2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Unclear Pronunciation of Stop Consonant Sounds in Patients with Parkinson’s Disease Following Deep Brain Stimulation

T. Sakurai, T. Yamamoto, Y. Yamanaka, S. Hirano, M. Abe, Y. Uji, A. Murata, Y. Higuchi, S. Kuwabara (Chiba-Ken, Japan)
Understanding the Needs and Concerns of Newly Diagnosed People with Parkinson’s Disease

V. Todaro, M. Feeney, A. Diaz, S. Rosenfeld, J. Gannon (New York, NY, USA)
Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system

J. Quintero, J. Slevin, Z. Guduru, J. Gurwell, G. Gerhardt, C. van Horne (Lexington, KY, USA)
Unilateral increase of blink reflex recovery cycle in drug-naive hemiparkinson syndrome.

G. Sciacca, G. Mostile, I. Disilvestro, G. Donzuso, R. Manna, G. Portaro, C. Rascunà, S. Salomone, F. Drago, A. Nicoletti, M. Zappia (Catania, Italy)
Unilateral Leg Freezing in Moyamoya Syndrome

R. Phattranonuthai, S. Frucht, P. Termsarasab (New York, NY, USA)
Unilateral leg tremor on sitting crossed-legged position as the initial manifestation of Parkinson’s disease

I. Park, W. Yoon (Seoul, Republic of Korea)
Unraveling biological processes implicated in MSA and PD by transcriptomic analysis

A. Perez-Soriano, M. Arnal, D. Giraldo, M. Fernandez, T. Botta-Orfila, Y. Compta, R. Fernández-Santiago, M. Ezquerra, D. Tartaglia, MJ. Martí (Barcelona, Spain)
Unscheduled disruption of Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD)

A. Blain, O. Lagha-Boukbiza, O. Gebus, M. Anheim, C. Tranchant (Strasbourg, France)
Unusual expression of fragile X premutation in a female patient: clinical and tractographic description

V. Ros-Castelló, E. Natera-Villalba, A. Sánchez-Sánchez, A. Gómez-López, P. Pérez-Torre, S. Fanjul, J. López-Sendón, A. Alonso-Cánovas, JC. Martínez-Castrillo, J. álvarez-Linera, I. Pareés (Madrid, Spain)
Update from the international MDSGene initiative: International team science to perform genotype-phenotype correlations for hereditary movement disorders

S. Petkovic, S. Schaake, J. Huang, H. Madoev, A. Rasheed, K. Lohmann, C. Klein, C. Marras (Luebeck, Germany)
Urodynamic study to distinguish multiple system atrophy from Parkinson’s disease

KW. Park, JH. Shin, NR. Choi, SY. Jo, MS. Choo, SJ. Chung (Seoul, Republic of Korea)
Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

Y. Li, Y. Guan, J. Wang, A. Calvin, J. Kyle, B. Miller (Indianapolis, IN, USA)
Use of Chemodenervation for Secondary Limb Dystonia in Parkinson’s Disease: A Single Center Experience

V. Veerappan, M. Brodsky (Portland, OR, USA)
Use of directional stimulation to localize and troubleshoot STN-related contralateral gaze deviation: a case report

C. Stahl, C. Cho, A. Mogilner, M. Pourfar (New York, NY, USA)
Use of e-PROMs in Parkinson’s disease clinics: A qualitative study of healthcare professionals perceptions

A. Khardali, L. Hughes, E. Lane (Cardiff, United Kingdom)
Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis

D. Kremens, V. Abler, S. Andes, N. Rashid, A. Shim (Philadelphia, PA, USA)
Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson’s disease

F. Hopfner, M. Wod, G. Höglinger, M. Blaabjerg, T. Roesler, G. Kuhlenbäumer, K. Christensen, G. Deuschl, A. Pottegård (Kiel, Germany)
Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)
Usefulness of Cardiac MIBG Scintigraphy, DAT scan and midbrain/pontine ratio to differentiate Parkinson disease from atypical parkinsonian syndrome

H. Fujita, K. Suzuki, Y. Watanabe, M. Hamaguchi, K. Hirata (Mibu, Japan)
Usefulness of Heart Rate Variability to Identify the Risk of Falling in Huntington’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)
Using Brain Atrophy and Visual Dysfunction to Predict Dementia in Parkinson’s Disease

L-A. Leyland, R. Mahmood, R. Weil (London, United Kingdom)
Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)
Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)
Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease

G. Thomas, L. Leyland, J. Acosta-Cabronero, R. Weil (London, United Kingdom)
Using whole genome sequencing and intronic sequence analysis to identify pathogenic variants in Parkin-related Parkinson’s Disease

R. Davis, K. Kumar, F. Edema-Hildebrand, J-S. Park, B. Koentjoro, V. Gayevskiy, M. Cowley, N. Blair, C. Sue (St Leonards, Australia)
Utilising Magnetic Resonance Spectroscopy to investigate synucleinopathies

N. Khalil, E. Matar, S. Duffy, S. Lewis (Camperdown, Australia)
Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)
Utility of Eye Movement Abnormalities in Differentiating Neurodegenerative versus non-Neurodegenerative Parkinsonism

A. Margolius, D. Hengartner, O. Hogue, X. Garcia, S. Patel, A. Ahmed, H. Fernandez, XX. Yu (Bogota, Colombia)
Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study

A. Fasano, JC. Parra, T. Gurevich, R. Jech, N. Kovács, P. Svenningsson, J. Szász, L. Bergmann, A. Johnson, O. Sanchez-Soliño, Z. Tang, L. Vela-Desojo (Toronto, ON, Canada)
Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z